News & Updates
Filter by Specialty:
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
16 Sep 2022
Smoking during surgical mask use may impair vascular function
Smoking during prolonged use of surgical facemasks due to the COVID-19 pandemic may further compromise vascular function, a study has shown.
Smoking during surgical mask use may impair vascular function
16 Sep 2022
Nephrotic proteinuria, kidney function deterioration tied to hypothyroidism
In patients with chronic kidney disease (CKD), nephrotic-range proteinuria and worsening kidney function are associated with hypothyroidism, a recent study has found.
Nephrotic proteinuria, kidney function deterioration tied to hypothyroidism
16 Sep 2022
Proximal gastrectomy OK for proximal advanced gastric cancer
For patients with proximal advanced gastric cancer (AGC), proximal gastrectomy (PG) appears to be a reasonable treatment option, particularly for those with small tumours, a recent study has found.
Proximal gastrectomy OK for proximal advanced gastric cancer
16 Sep 2022
Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
Ferric carboxymaltose (FCM) is as good as ferric derisomaltose (FDI) in the treatment of iron-deficiency anaemia, although FCM leads to a higher frequency of hypophosphatemia, according to data from the PHOSPHARE-IBD study.
Hypophosphatemia events more frequent with ferric carboxymaltose vs ferric derisomaltose
16 Sep 2022
Maximal androgen blockade the prime prostate cancer treatment option in older patients
Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.
Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
